H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CAPR stock, giving a Buy rating today.
Joseph Pantginis’s rating is based on several promising developments surrounding Capricor Therapeutics. The FDA’s acceptance of the Biologics License Application (BLA) for deramiocel, a treatment for Duchenne muscular dystrophy (DMD) cardiomyopathy, and the granting of Priority Review highlight the potential for this therapy to address a significant unmet medical need. Deramiocel has demonstrated improvements in cardiac function in clinical trials, which could make it a first-in-class option for DMD patients, a condition with no current approved therapies.
Furthermore, Capricor’s strategic preparations for potential approval and commercialization, including scaling up manufacturing and forming key partnerships, position the company well for future success. The company’s regulatory strategy and focus on DMD-cardiomyopathy allow for a de-risked and expedited path to market, potentially accelerating the availability of this novel therapy. These factors combined suggest a strong growth potential for Capricor, justifying the Buy rating.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $43.00 price target.